Prolia vs Evenity
A side-by-side look at two bone health medications advertised on TV. Informational only — not medical advice.
| US Prolia | US Evenity | |
|---|---|---|
| Generic name | denosumab | romosozumab |
| Drug class | RANKL Inhibitor (Biologic) | Sclerostin Inhibitor (Biologic) |
| Treats | Osteoporosis | Osteoporosis (high fracture risk) |
| Category | Bone Health | Bone Health |
| Manufacturer | Amgen | Amgen/UCB |
| Year approved | 2010 | 2019 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | $120M | $70M |
| Common side effects | Low blood calcium, Serious infections, Back and joint pain, Skin reactions | Heart attack or stroke risk, Joint pain, Headache, Low blood calcium |
Frequently asked questions
Is Prolia or Evenity better?
Neither is universally "better." Prolia (denosumab) and Evenity (romosozumab) are both used for bone health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Prolia and Evenity?
Prolia is a RANKL Inhibitor (Biologic) made by Amgen, while Evenity is a Sclerostin Inhibitor (Biologic) made by Amgen/UCB. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Prolia has the larger estimated TV advertising budget of the two.